We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The current design of the IOL is characterized by ...

LOS ANGELES — The accommodative Crystalens intraocular lens (IOL) (Bausch + Lomb) achieved better intermediate visual acuity but not as good near visual acuity compared with the ReStor +3 multifocal ...

As the eyeonics Crystalens becomes more popular, there are patients requesting the lens who do not appear to be candidates for the new accommodative IOL. The relatively uncharted territory of bioptics ...

Bausch + Lomb, the global eye health company has launched a national TV campaign for its intraocular lens, Crystalens, in several markets. The campaign features Broadway, film and TV actress Florence ...

Bausch & Lomb is launching an ad campaign for a product for cataracts that has to be implanted surgically. The direct-to-consumer advertising campaign touts Crystalens, an intraocular lens, to baby ...

Bausch & Lomb has introduced Crystalens AO, an aberration free accommodating intraocular lens with aspheric optics, according to a Bausch & Lomb news release. The Crystalens AO has prolate aspheric ...

ALISO VIEJO, Calif., May 10, 2005 -- Eyeonics, Inc. today announced that the crystalens TM procedure can now be privately purchased by Medicare beneficiaries. Crystalens is the first and only ...

Bausch + Lomb has announced it is extending the rebate program for patients who have the company’s Crystalens accommodating intraocular lens implanted before March 31, 2011. Patients will be eligible ...

ALISO VIEJO, Calif., Jan. 4-- Bausch & Lomb today announced that it is launching the Crystalens® AO, the first aberration-free accommodating intraocular lens (IOL) with aspheric optics to cataract ...

SAN FRANCISCO--For most people, the need to wear eyeglasses to read is an inevitable part of aging. The eye's natural lens hardens and loses its ability to change shape, making it more difficult to ...

A recent article in the Herald-Tribune> discussed the Crystalens. As one of the 18 original investigators for the clinical trial that led to FDA approval, I felt I should add some balance to the story ...